Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6896275 | 0.88 | TSHR (0.42) | TSHRSMN1; SMN2ALDH1A1LMNACYP3A4 | |
| SCHEMBL5505348 | 0.82 | ALDH1A1 (0.48) | PRKCAPRKCDTSHRALDH1A1LMNA | |
| SCHEMBL348985 | 0.82 | PRKCA (0.49) | PRKCAPRKCDTSHRALDH1A1CYP3A4 | |
| SCHEMBL18558920 | 0.81 | TSHR (0.35) | PRKCAPRKCDTSHRALDH1A1LMNA | |
| SCHEMBL6896626 | 0.81 | TSHR (0.39) | TSHRSMN1; SMN2ALDH1A1LMNACYP3A4 | |
| SCHEMBL22644000 | 0.81 | TSHR (0.34) | PRKCAPRKCDTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4439992 | 0.80 | TSHR (0.42) | TSHRSMN1; SMN2ALDH1A1LMNACYP3A4 | |
| SCHEMBL1218297 | 0.80 | TSHR (0.42) | TSHRSMN1; SMN2ALDH1A1LMNACYP3A4 | |
| SCHEMBL2990189 | 0.80 | TSHR (0.42) | TSHRSMN1; SMN2ALDH1A1LMNACYP3A4 | |
| SCHEMBL21566978 | 0.80 | PRKCA (0.47) | PRKCAPRKCDTSHRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | PRKCA 4414/4885PRKCD 4286/4885TSHR 1502/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | PRKCA 4275/4885PRKCD 3398/4885TSHR 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.